4D Molecular Therapeutics, Inc.
NASDAQ · us_market
No AI insight generated yet for this ticker.
4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. The company's lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macular degeneration and diabetic macular edema. It is also developing 4D-710, which is in early-stage study for the treatment of cystic fibrosis; 4D-175 that is in preclinical stage for treating geographic atrophy; and 4D-725, which is in preclinical stage for the treatment of alpha-1 anti-trypsin deficiency lung disease. 4D Molecular Therapeutics, Inc. has collaboration and licensing agreements with Otsuka Pharmaceutical Co., Ltd. The company was founded in 2013 and is headquartered in EmeryVille, California.
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| StateStreet | passive | 2.71M | $25.21M | 0.00% | Added+0.7% | 2026-03-31 |
| RenTech | quant | 578.3K | $5.38M | 0.01% | Added+12.7% | 2026-03-31 |
| TwoSigma | quant | 124.3K | $1.16M | 0.00% | Trimmed-63.2% | 2026-03-31 |
| Wellington | fundamental | 108.9K | $1.01M | 0.00% | Trimmed-16.4% | 2026-03-31 |
| FidelityFMR | fundamental | 70.1K | $652.60K | 0.00% | Added+6.8% | 2026-03-31 |
| DEShaw | quant | 24.0K | $223.72K | 0.00% | Trimmed-78.5% | 2026-03-31 |
| TRowePrice | fundamental | 42.4K | $396 | 0.00% | Added+9.5% | 2026-03-31 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-08-10upcoming | -1.01 | — | — |
| 2026-05-07 | -1.00 | -1.01 | -1.45% |
| 2026-03-18 | -0.53 | 0.43 | +181.44% |
| 2025-11-10 | -0.98 | -1.01 | -2.79% |
| 2025-08-11 | -0.69 | -0.98 | -41.37% |
| 2025-05-08 | -0.86 | -0.86 | +0.24% |
| 2025-02-28 | -0.84 | -0.90 | -7.41% |
| 2024-11-13 | -0.70 | -0.79 | -12.16% |
| 2024-08-08 | -0.71 | -0.63 | +10.99% |
| 2024-05-09 | -0.76 | -0.66 | +12.80% |
| 2024-02-29 | -0.73 | -0.77 | -5.80% |
| 2023-11-09 | -0.60 | -0.24 | +60.22% |
| 2023-08-09 | -0.77 | -0.77 | +0.43% |
| 2023-05-10 | -0.90 | -0.88 | +2.22% |
| 2023-03-15 | -0.73 | -0.84 | -15.07% |
| 2022-11-08 | -0.91 | -0.79 | +13.42% |
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| FDMT | +9.02% | +17.14% | +32.13% | +173.76% |
| XLV | +2.97% | -4.64% | -3.44% | +12.69% |
| Alpha (stock − sector) | +6.05% | +21.78% | +35.58% | +161.07% |